Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504294 · ClinicalTrials.gov registry record · Phase 3
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
NCT02504294: Completed Phase 3 study, sponsored by Pfizer.
NCT02504294 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 432 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02504294, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
Study Summary
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
Interventions
- DRUG IV Iron
- BIOLOGICAL Epoetin Hospira Arm
- OTHER Standard of Care Arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2015-07-13 |
| Est. Completion | 2016-07-16 |
| Phase | Phase 3 |
What the finished NCT02504294 record still lists
NCT02504294 is an interventional study that assigns participants to a tested intervention. The registered 432 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 3 interventions - of which IV Iron is the first listed.
NCT02504294 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02504294 about?
NCT02504294 is a clinical study titled "A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis". A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
What is the current status of trial NCT02504294?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2015-07-13. Estimated completion is 2016-07-16.
What interventions are being tested in trial NCT02504294?
The interventions under investigation include: IV Iron (DRUG), Epoetin Hospira Arm (BIOLOGICAL), Standard of Care Arm (OTHER).
Who is sponsoring clinical trial NCT02504294?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02504294's enrollment target sits among peer trials
432 876th of 2000 higher than 1,124 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
- NCT05806164 · 432 participants · Phase 4
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI